Literature DB >> 25926432

Gut Microbiota-Mediated Drug-Antibiotic Interactions.

Dong-Hyun Kim1.   

Abstract

Xenobiotic metabolism involves the biochemical modification of drugs and phytochemicals in living organisms, including humans and other animals. In the intestine, the gut microbiota catalyzes the conversion of hydrophilic drugs into absorbable, hydrophobic compounds through hydroxyzation and reduction. Drugs and phytochemicals are transformed into bioactive (sulfasalazine, lovastatin, and ginsenoside Rb1), bioinactive (chloramphenicol, ranitidine, and metronidazole), and toxic metabolites (nitrazepam), thus affecting the pharmacokinetics of the original compounds. Antibiotics suppress the activities of drug-metabolizing enzymes by inhibiting the proliferation of gut microbiota. Antibiotic treatment might influence xenobiotic metabolisms more extensively and potently than previously recognized and reduce gut microbiota-mediated transformation of orally administered drugs, thereby altering the systemic concentrations of intact drugs, their metabolites, or both. This review describes the effects of antibiotics on the metabolism of drugs and phytochemicals by the gut microbiota.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25926432     DOI: 10.1124/dmd.115.063867

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  30 in total

Review 1.  Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry?

Authors:  Hollie I Swanson
Journal:  Drug Metab Dispos       Date:  2015-08-10       Impact factor: 3.922

Review 2.  The Human Microbiome and Understanding the 16S rRNA Gene in Translational Nursing Science.

Authors:  Nancy J Ames; Alexandra Ranucci; Brad Moriyama; Gwenyth R Wallen
Journal:  Nurs Res       Date:  2017 Mar/Apr       Impact factor: 2.381

3.  Gut Microbiota Modulation Attenuated the Hypolipidemic Effect of Simvastatin in High-Fat/Cholesterol-Diet Fed Mice.

Authors:  Xuyun He; Ningning Zheng; Jiaojiao He; Can Liu; Jing Feng; Wei Jia; Houkai Li
Journal:  J Proteome Res       Date:  2017-04-10       Impact factor: 4.466

4.  Gut Microbiome and Response to Cardiovascular Drugs.

Authors:  Sony Tuteja; Jane F Ferguson
Journal:  Circ Genom Precis Med       Date:  2019-08-28

Review 5.  Can manipulation of gut microbiota really be transformed into an intervention strategy for cardiovascular disease management?

Authors:  Khalid Mehmood; Afrasim Moin; Talib Hussain; Syed Mohd Danish Rizvi; D V Gowda; Shazi Shakil; M A Kamal
Journal:  Folia Microbiol (Praha)       Date:  2021-10-26       Impact factor: 2.099

6.  Regulation of Hepatic Drug-Metabolizing Enzymes in Germ-Free Mice by Conventionalization and Probiotics.

Authors:  Felcy Pavithra Selwyn; Sunny Lihua Cheng; Curtis D Klaassen; Julia Yue Cui
Journal:  Drug Metab Dispos       Date:  2015-11-19       Impact factor: 3.922

Review 7.  Drug Response Diversity: A Hidden Bacterium?

Authors:  Nadji Hannachi; Laurence Camoin-Jau
Journal:  J Pers Med       Date:  2021-04-25

8.  Plateau hypoxia attenuates the metabolic activity of intestinal flora to enhance the bioavailability of nifedipine.

Authors:  Juanhong Zhang; Yuyan Chen; Yuemei Sun; Rong Wang; Junmin Zhang; Zhengping Jia
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

9.  A novel approach for the prediction of species-specific biotransformation of xenobiotic/drug molecules by the human gut microbiota.

Authors:  Ashok K Sharma; Shubham K Jaiswal; Nikhil Chaudhary; Vineet K Sharma
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

Review 10.  Pharmacological Efficacy/Toxicity of Drugs: A Comprehensive Update About the Dynamic Interplay of Microbes.

Authors:  Juan Antonio Gimenez-Bastida; Lucia Martinez Carreras; Angela Moya-Pérez; José Moisés Laparra Llopis
Journal:  J Pharm Sci       Date:  2017-10-26       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.